SEARCH:   Advanced

Blood, 1 August 2004, Vol. 104, No. 3, pp. 626-633. Prepublished online as a Blood First Edition Paper on February 24, 2004; DOI 10.1182/blood-2003-06-2094. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-06-2094v1 104/3/626    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pfreundschuh, M. Articles by the German High-Grade Non-Hodgkin's Lymphoma Study Group, Search for Related Content PubMed PubMed Citation Articles by Pfreundschuh, M. Articles by the German High-Grade Non-Hodgkin's Lymphoma Study Group, Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND CLINICAL TRIALS Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Michael Pfreundschuh, Lorenz Trümper, Marita Kloess, Rudolf Schmits, Alfred C. Feller, Christian Rudolph, Marcel Reiser, Dieter K. Hossfeld, Bernd Metzner, Dirk Hasenclever, Norbert Schmitz, Bertram Glass, Christian Rübe, Markus Loeffler, and the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) From the Saarland University Medical School, Homburg/Saar, Germany; Universitätsklinikum Göttingen, Göttingen, Germany; Institut für Medizinische Informatik, Statistik und Epidemiologie (IMISE) Universität Leipzig, Leipzig, Germany; Institut für Pathologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Klinikum Cottbus, Cottbus, Germany; Med Klinik der Universität zu Köln, Köln, Germany; Universitätsklinikum Eppendorf, Hamburg, Germany; Klinikum Oldenburg, Oldenburg, Germany; and Krankenhaus St Georg, Hamburg, Germany. The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21) is standard chemotherapy for aggressive lymphomas. To determine whether CHOP given every 2 weeks (CHOP-14) or the addition of etoposide (CHOEP-21, CHOEP-14) can improve results in patients ages 18 to 60 years with good prognosis (normal lactic dehydrogenase [LDH] level), 710 patients were randomized to 6 cycles of CHOP-21, CHOP-14, CHOEP-21 (CHOP plus etoposide 100 mg/m2 days 1-3), or CHOEP-14 in a 2 x 2 factorial study design. Patients in the biweekly regimens received granulocyte colony-stimulating factor (G-CSF) starting from day 4. Patients received radiotherapy (36 Gy) to sites of initial bulky disease and extranodal disease. CHOEP achieved better complete remission (87.6% versus 79.4%; P = .003) and 5-year event-free survival rates (69.2% versus 57.6%; P = .004, primary end point) than CHOP, whereas interval reduction improved overall survival (P = .05; P = .044 in the multivariate analysis). Although the CHOEP regimens induced more myelosuppression, all regimens were well tolerated. CHOEP should be the preferred chemotherapy regimen for young patients with good-prognosis (normal LDH level) aggressive lymphoma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Is more better? David Linch Blood 2004 104: 596-597. [Full Text] [PDF] This article has been cited by other articles: D. Kube, T.-D. Hua, F. von Bonin, N. Schoof, S. Zeynalova, M. Kloss, D. Gocht, B. Potthoff, M. Tzvetkov, J. Brockmoller, et al. Effect of Interleukin-10 Gene Polymorphisms on Clinical Outcome of Patients with Aggressive Non-Hodgkin's Lymphoma: An Exploratory Study Clin. Cancer Res., June 15, 2008; 14(12): 3777 - 3784. [Abstract] [Full Text] [PDF] G. P. Canellos What Constitutes "Improved Prognosis"? J. Clin. Oncol., April 20, 2008; 26(12): 1913 - 1914. [Full Text] [PDF] M. Ziepert, R. Schmits, L. Trumper, M. Pfreundschuh, M. Loeffler, and On behalf of the German High-Grade Non-Hodgkin's L Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma Ann. Onc., April 1, 2008; 19(4): 752 - 762. [Abstract] [Full Text] [PDF] M. Pfreundschuh, C. Zwick, S. Zeynalova, U. Duhrsen, K.-H. Pfluger, T. Vrieling, R. Mesters, H.-G. Mergenthaler, H. Einsele, M. Bentz, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Ann. Onc., March 1, 2008; 19(3): 545 - 552. [Abstract] [Full Text] [PDF] L. Trumper, C. Zwick, M. Ziepert, K. Hohloch, R. Schmits, M. Mohren, R. Liersch, M. Bentz, U. Graeven, U. Wruck, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens Ann. Onc., March 1, 2008; 19(3): 538 - 544. [Abstract] [Full Text] [PDF] C. H. Moskowitz, P. A. Hamlin, J. Gabrilove, J. R. Bertino, C. S. Portlock, D. J. Straus, A. N. Gencarelli, S. D. Nimer, and A. D. Zelenetz Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma Ann. Onc., November 1, 2007; 18(11): 1842 - 1850. [Abstract] [Full Text] [PDF] N. M. Kuderer, D. C. Dale, J. Crawford, and G. H. Lyman Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review J. Clin. Oncol., July 20, 2007; 25(21): 3158 - 3167. [Abstract] [Full Text] [PDF] J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF] A. Kolstad, H. Holte, A. Fossa, G. F. Lauritzsen, P. Gaustad, and D. Torfoss Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen Haematologica, January 1, 2007; 92(1): 139 - 140. [Abstract] [Full Text] [PDF] M.A. Dawson, A.P. Schwarer, C. McLean, P. Oei, L.J. Campbell, E. Wright, J. Shortt, and A.M. Street Aids-related plasmablastic lymphoma of the oral cavity associated with an IgH/MYC translocation treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A Haematologica, January 1, 2007; 92(1): e11 - e12. [Abstract] [Full Text] [PDF] V Boehme, S Zeynalova, M Kloess, M Loeffler, U Kaiser, M Pfreundschuh, and N Schmitz Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Ann. Onc., January 1, 2007; 18(1): 149 - 157. [Abstract] [Full Text] [PDF] T. M. Habermann Antibody Therapy in Aggressive Lymphomas Hematology, January 1, 2007; 2007(1): 257 - 264. [Abstract] [Full Text] [PDF] T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF] C. Dang and C. Hudis Can Granulocyte-Colony Stimulating Factor Worsen Anemia? J. Clin. Oncol., July 1, 2006; 24(19): 2985 - 2986. [Full Text] [PDF] D. A. Stewart, N. Bahlis, K. Valentine, A. Balogh, L. Savoie, D. G. Morris, A. Jones, C. Brown, and J. A. Russell Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma Blood, June 15, 2006; 107(12): 4623 - 4627. [Abstract] [Full Text] [PDF] N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Blood, May 15, 2006; 107(10): 3832 - 3840. [Abstract] [Full Text] [PDF] I. Oschlies, W. Klapper, M. Zimmermann, M. Krams, H.-H. Wacker, B. Burkhardt, L. Harder, R. Siebert, A. Reiter, and R. Parwaresch Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial Blood, May 15, 2006; 107(10): 4047 - 4052. [Abstract] [Full Text] [PDF] B. Glass, M. Kloess, M. Bentz, G. Schlimok, W. E. Berdel, A. Feller, L. Trumper, M. Loeffler, M. Pfreundschuh, N. Schmitz, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma Blood, April 15, 2006; 107(8): 3058 - 3064. [Abstract] [Full Text] [PDF] P. G. Gobbi, C. Broglia, F. Valentino, C. Mammi, M. Lombardo, F. Merli, S. Luminari, G. Polimeno, A. Riezzo, P. Lambelet, et al. The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL) Ann. Onc., April 1, 2006; 17(4): 676 - 682. [Abstract] [Full Text] [PDF] J. S. Abramson T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist, April 1, 2006; 11(4): 384 - 392. [Abstract] [Full Text] [PDF] A. M. Brade and I. F. Tannock Scheduling of Radiation and Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Repopulation As a Cause of Treatment Failure? J. Clin. Oncol., March 1, 2006; 24(7): 1020 - 1022. [Full Text] [PDF] L. Wojnowski, B. Kulle, M. Schirmer, G. Schluter, A. Schmidt, A. Rosenberger, S. Vonhof, H. Bickeboller, M. R. Toliat, E.-K. Suk, et al. NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity Circulation, December 13, 2005; 112(24): 3754 - 3762. [Abstract] [Full Text] [PDF] B. Coiffier State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6387 - 6393. [Abstract] [Full Text] [PDF] S. A. Gregory and L. Trumper Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann. Onc., September 1, 2005; 16(9): 1413 - 1424. [Abstract] [Full Text] [PDF] J. S. Abramson and M. A. Shipp Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach Blood, August 15, 2005; 106(4): 1164 - 1174. [Abstract] [Full Text] [PDF] F. Reyes, E. Lepage, G. Ganem, T. J. Molina, P. Brice, B. Coiffier, P. Morel, C. Ferme, A. Bosly, P. Lederlin, et al. ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma N. Engl. J. Med., March 24, 2005; 352(12): 1197 - 1205. [Abstract] [Full Text] [PDF] G. H. Lyman, D. C. Dale, J. Friedberg, J. Crawford, and R. I. Fisher Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study J. Clin. Oncol., November 1, 2004; 22(21): 4302 - 4311. [Abstract] [Full Text] [PDF] C. Engel, M. Scholz, and M. Loeffler A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy Blood, October 15, 2004; 104(8): 2323 - 2331. [Abstract] [Full Text] [PDF] B. Coiffier, G. Salles, M. Pfreundschuh, and M. Loeffler Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma Blood, September 1, 2004; 104(5): 1584 - 1586. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020